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Summary 1 
 2 
The use of Veno-Arterial ExtraCorporeal Membrane Oxygenation (VA-ECMO) as a salvage 3 
therapy in cardiogenic shock is becoming of current practice. While VA-ECMO is potentially 4 
a life-saving technique, results are sometimes mitigated, emphasizing the need for selecting 5 
the right indication in the right patient. This relies upon a clear definition of the individual 6 
therapeutic project, including the potential for recovery as well as the possible complications 7 
associated with VA-ECMO. To maximize the benefits of VA-ECMO, the basics of 8 
extracorporeal circulation should be perfectly understood since VA-ECMO can sometimes be 9 
detrimental. Hence, to be successful, VA-ECMO should be used by teams with sufficient 10 
experience and initiated after a thorough multidisciplinary discussion considering patient’s 11 
medical history, pathology as well the anticipated evolution of the disease.  12 
  13 
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Introduction 1 
 2 
Veno-Arterial Extra-Corporeal Membrane Oxygenation (VA-ECMO) or Extra-Corporeal Life 3 
Support (ECLS) are two terms that designate devices originally created to replace heart and 4 
lung functions. Both denominations are synonymous and we will keep the term “VA-ECMO” 5 
throughout this review for the sake of consistency. While VA-ECMO was initially dedicated 6 
to cardiac surgery (i.e. cardiopulmonary bypass), technical evolutions such as pump 7 
miniaturization, better circuit biocompatibility and easier cannulation have enabled this 8 
technique to enter the Intensive Care Unit (ICU). VA-ECMO was tested in various indications 9 
[1–7]. Nevertheless, because of inconsistent success rates [1–7], significant complications, 10 
and high-related costs, it is of paramount importance to accurately identify the patients in 11 
whom VA-ECMO may be reasonably initiated. 12 
The goal of this article is to describe some key technical aspects of VA-ECMO, to present a 13 
literature overview on the use of VA-ECMO in critically ill patients and ultimately to help the 14 
intensivist to identify the appropriate indications for VA-ECMO.  15 
 16 
  17 
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Principles and technical aspects 1 
 2 
The principle is directly derived from extra corporeal circulation techniques used during 3 
cardiac surgery. Venous deoxygenated blood is mechanically suctioned, from a large central 4 
vein through a venous cannula, by a centrifugal pump. It is then oxygenated, warmed and 5 
restituted into systemic circulation through an arterial cannula. Hence, VA-ECMO is used to 6 
assist the heart by insuring part or all the systemic blood flow (Figure 1).  7 
Vascular access - Peripheral versus Central VA-ECMO  8 
Among VA-ECMO circuits, a distinction has to be made between those inserted centrally or 9 
peripherally.  10 
Peripheral ECMO 11 
The typical configuration for peripheral VA-ECMO involves blood drainage from a femoral 12 
venous access and reinfusion through a femoral arterial cannula. With this configuration, the 13 
reinfusion cannula generates a retrograde flow up in the aorta that may encounter the 14 
anterograde flow generated by the left ventricle [8].  15 
For peripheral VA-ECMO configurations, percutaneous ultrasound guided femoro-femoral 16 
access is usually a quick and efficient way of insertion [9], even though it can become more 17 
difficult in case of profound arterial hypotension or hemostasis disorders for instance. The 18 
alternative is a surgical insertion that allows for a direct visualization of the vessels as well as 19 
a simultaneous insertion of the reperfusion cannula (see below) but depends upon the 20 
availability of the surgical team.  21 
Whatever the insertion technique chosen, peripheral VA-ECMOs carries specific 22 
complications. First, peripheral VA-ECMO may lead to an obstruction of the common 23 
femoral artery that can cause lower limb ischemia [10–13]. It is thus advised to place a 24 
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reperfusion catheter in the ipsilateral superficial femoral artery [11]. Another drawback of 1 
peripheral VA-ECMO is the competition between the retrograde flow generated by the VA-2 
ECMO and the native anterograde flow [8]. This competition may induce or worsen 2 types 3 
of complications:  1) LV overload; and 2) Harlequin syndrome.  4 
Left Ventricle (LV) overload 5 
Even when the VA-ECMO support is fully covering the cardiac output, there is still blood 6 
entering the cardiopulmonary circulation since part of the coronary circulation ends up into 7 
the cardiac chambers, including the left atrium or ventricle, through the Thebesian veins [14]. 8 
This residual filling of a failing left ventricle (LV) may cause a pulmonary edema especially 9 
with peripheral VA-ECMO. In this case, whilst VA-ECMO unloads the right heart, the 10 
increase in the LV afterload generated by the assistance itself may overload the LV [15]. 11 
Thus, inotropes should be maintained or introduced in case of ventricular dilation or evidence 12 
of pulmonary edema. Mean arterial pressure should always be tightly controlled, and adapted 13 
to both organ perfusion and cardiac function. In some cases, vasodilators may also be used, in 14 
order to adjust the mean arterial pressure.  15 
Additional therapies may be necessary to unload the LV. The use of an Intra-Aortic Balloon 16 
Pump (IABP) was reported to be associated with  a reduction in  the LV afterload [15,16]. It 17 
may help to restore pulsatile condition, and lower the Pulmonary Artery Occlusion Pressure in 18 
VA-ECMO patients [17,18]. Nevertheless, although an IABP may improve macrocirculatory 19 
parameters without significant complications [19], its benefits remain uncertain [20,21].  20 
In case of refractory pulmonary edema, a LV vent may be added to the extracorporeal circuit. 21 
Percutaneous Trans-Aortic, or surgical vent are possible in this context. Recent data suggest 22 
that either the percutaneous trans-Aortic devices or the surgical vents may be beneficial to 23 
unload the LV in case of pulmonary edema [22–25] and improve survival in this context [26].  24 
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Since there is no argument for a clear benefit of one technique over the other [25,27,28], the 1 
choice of a percutaneous or a surgical vent should be based upon the VA-ECMO settings 2 
(centrally or peripherally inserted - see below -) and the availability of the surgical team.  3 
Harlequin Syndrome 4 
In case of a concomitant respiratory failure, and especially in the cardiac recovery period, the 5 
blood flow competition may also cause a Harlequin syndrome [8,29,30]. Indeed, if the 6 
residual heart function is able to generate a native perfusion, the interface (or watershed) 7 
between the anterograde (native and poorly oxygenated blood) and retrograde (assisted and 8 
well oxygenated blood) flows may be located at the level of the supra-aortic trunks. Its 9 
clinical expression (cyanosis in the upper part of the body, with subsequent risk of cerebral or 10 
myocardial ischemia, constrasting with pink well-perfused lower part of the body, generating 11 
this aspect of “Harlequin”) results from a selective upper body hypoxia.  12 
It is recommended [31] to monitor oxygen saturation at left hand, while getting blood sample 13 
for arterial blood gas analysis on the right hand, in order to detect promptly a discrepancy 14 
between right and left arms. Managing a Harlequin syndrome may include: VA-ECMO 15 
withdrawal if cardiac recovery is sufficient, increase of the VA-ECMO flow to reduce the 16 
relative participation of the native hypoxemic flow to brain perfusion,  “centralization”, or 17 
addition of a partial reinjection cannula into the  internal jugular vein (so called veno-arterial-18 
venous ECMO, VAV-ECMO) [32]. If the circulatory support is no longer needed, but 19 
respiratory support is still requested, a switch toward a veno-venous ECMO can be 20 
considered. 21 
Central ECMO 22 
Central VA-ECMOs are always inserted surgically. The venous cannula is placed in the right 23 
atrium and the arterial cannula in the ascending aorta. The oxygenated blood is injected 24 
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anterogradely in the aorta through the arterial cannula. Thus, with central ECMO there is no 1 
competition between with the native heart thereby reducing the risk of LV overload and 2 
virtually no risk of Harlequin syndrome. 3 
At the population level, no cannulation site has proven its superiority over the other in terms 4 
of outcome or hemodynamic stability [33]. The choice of the best technique essentially 5 
depends on the situation (emergent or less emergent VA-ECMO), on the indication and on the 6 
risk of complications at the individual level. Central VA-ECMO is typically considered in 7 
case of post-cardiopulmonary bypass related heart failure. It needs a surgical team to be 8 
inserted and is associated with a higher risk of complications such as mediastinitis or 9 
bleeding, as compared with peripheral VA-ECMO [12,33]. Peripheral VA-ECMO, whether 10 
inserted surgically or percutaneously, can be implanted faster, but is associated with higher 11 
risk of LV overload or Harlequin syndrome. Thus, any emergent indication for 12 
cardiorespiratory assistance should typically lead to prefer peripheral insertion while central 13 
VA-ECMO can be considered as an alternative to peripheral VA-ECMO in case of refractory 14 
pulmonary edema, Harlequin syndrome or limb ischemia occurring downstream the femoral 15 
arterial cannula despite reperfusion.   16 
Gas exchanges determinants during VA-ECMO 17 
VA-ECMO creates a Venous to Arterial shunt, bypassing the native cardiopulmonary 18 
circulation. In order to allow for adequate gas exchanges, the VA-ECMO circuit has to 19 
provide optimal oxygen delivery and CO2 removal. In the artificial lung (i.e the oxygenator), 20 
as well as in the native lungs, blood oxygenation and decarboxylation result from double 21 
convective exchanges occurring alongside a semipermeable membrane. Therefore, during 22 
VA-ECMO, PaO2 and PaCO2 both depend upon extra-corporeal circulation settings and 23 
patient’s characteristics.  24 
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Indeed, the Cardiac Output (CO) and the Pump Flow Rates (PFR), and more specifically their 1 
ratio (PFR/CO), are both of crucial importance. If the PFR/CO ratio is close to 0 (i.e. the 2 
artificial shunt is null), the fraction of oxygenated blood coming from VA-ECMO is 3 
negligible and so is the benefit in terms of PaO2. However such a situation should not be 4 
encountered since the minimal Pump Flow Rates should never be lower than 1500 ml/min 5 
(risk of circuitry thrombosis, or back flow into the circuitry). If the PFR/CO is close to 1, the 6 
CO entirely flows through the membrane, and may thus be oxygenated. Nevertheless, at high 7 
PFR, the oxygenator performance by itself and more precisely the quality of the membrane 8 
may limit oxygen transfer. Indeed, the membrane may be deteriorated by clots, thereby 9 
reducing its performance and its lifetime.  10 
Another determinant is the Inspired Oxygen Fraction (FiO2). The latter drives the oxygen 11 
partial pressure on the VA-ECMO side of the oxygenator, and thus also determines the 12 
gradient for oxygen exchange across the membrane. Sweep gas flow which is a major 13 
determinant for CO2 removal, has almost no impact on O2 exchanges unless it is turned down 14 
close to zero. Indeed, the magnitude of oxygen gradient through the membrane as well as its 15 
high permeability for oxygen, explain that oxygen transfer rate is very high.  16 
Blood decarboxylation depends on PFR/CO ratio [34] and sweep gas flow. At membrane 17 
entry, CO2 partial pressure is zero and CO2 removing gradient equals CO2 venous partial 18 
pressure. As CO2 exchange occurs alongside the membrane, the gradient decreases, thereby 19 
reducing CO2 transfer, unless the sweep gas is sufficient to “wash” out the CO2 accumulated 20 
on the VA-ECMO side of the membrane.  21 
Circulatory support during VA-ECMO  22 
VA-ECMO is used to restore adequate systemic perfusion. Pump flow depends on the size of 23 
the vascular accesses, venous circuit resistance, and the pump itself.  24 
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For a given Pump Flow Rate, the size of the venous cannula is a major determinant of the 1 
inflow. Indeed, pump preload depends on the resistance (or the size) of the venous cannula 2 
and on the blood volume in the inferior vena cava and the right atrium. The position of the 3 
venous cannula is optimal when the tip is located in the right atrium. When positioned in the 4 
inferior or the superior vena cava, the risk of venous collapse is more important.  5 
Pump rotation speed is an important determinant of the flow rate and of the pressure gradient. 6 
Modern VA-ECMO machines use preferentially centrifugal pumps, which allow for high 7 
rotation speed and flow rate with a lower risk of hemolysis. Increasing pump rotation speed 8 
increases the flow rate (and decreases the right atrial pressure [35]), unless the suction 9 
generated precipitates a transient venous or atrial collapse (Kicking lines) (Figure 2). In such 10 
a situation, one must decrease pump rotation speed and/or administer intravascular fluids in 11 
order to restore venous/atrial transmural pressure. In addition, to avoid complications such as 12 
hemolysis, the maximum theoretical pressure generated by the pump should not exceed -300 13 
mmHg on the venous side, and +400 mmHg on the arterial side [31].  14 
The impact of the size of the arterial cannula is less important as the pump easily overcomes 15 
the resulting afterload. Nevertheless, a too small arterial cannula may cause hemolysis, alter 16 
the performance of the pump and limits the flow. Similarly, mean arterial pressure should be 17 
tightly controlled in order to limit the increase in afterload and avoid deleterious 18 
consequences (see “Specific Management section”). 19 
 20 
 21 
 22 
 23 
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Specific Management during VA-ECMO 1 
 2 
While non-specific ICU care should be provided during VA-ECMO management, careful 3 
attention should be paid on VA-ECMO and ventilator settings as well as anticoagulation 4 
therapy.  5 
ECMO management 6 
Modifying pump flow rates can induce substantial alteration in hematosis or worsen a 7 
preexisting cardio-respiratory insufficiency. Therefore, daily ICU care should be provided 8 
with great caution. For instance, a simple patient mobilization can cause accidental 9 
decannulation, with catastrophic consequences. VA-ECMO could also prevent from 10 
appropriately positioning the patient. During patients’ positioning it is of paramount 11 
importance to carefully verify the cannula, in order to prevent any extracorporeal circulation 12 
mobilization or soft tissue alteration. Semi-recombinant position may be difficult with a 13 
peripheral VA-ECMO, while central VA-ECMO is not compatible with prone positioning. 14 
Prone positioning has been described during peripheral Veno-Venous-ECMO in case of 15 
refractory Acute Respiratory Distress Syndrome (ARDS), as described by Otterspoor [36], 16 
Kimmoun [37] and Kipping [38]; however, in peripheral VA-ECMO, the risks of kinking of 17 
the reperfusion line or accidental withdrawal of the arterial cannula justify that in case of 18 
refractory ARDS while on VA-ECMO, a safer alternative to prone positioning can be the 19 
addition of a reinjection cannula into the right internal jugular vein (Veno-Arterial-Venous -20 
ECMO). 21 
Finally, out-of-ICU exams are also more difficult in patients under ECMO. Double pliers 22 
must always be readily available to interrupt quickly the extracorporeal circulation. A manual 23 
wheel should always be present to replace the pump in case of outage or dysfunction. The 24 
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membrane should be checked daily, particularly for clots formation (dark red deposit on the 1 
membrane). If requested, blood gases can be performed before and after the membrane to 2 
evaluate its performance. When blood gases are performed after the membrane, oxygen 3 
partial pressure should be greater than 200 mmHg. Arterial and Venous cannulas should also 4 
be carefully screened. There should be a substantial color difference between dark venous 5 
blood and red arterial blood. Non-cyclic oscillations of the circuit associated with decrease in 6 
the blood flow, should prompt the team to check the inflow pressure and take the appropriate 7 
decisions (decrease Pump Flow Rate, administer fluids, etc). Daily examination of 8 
cannulation sitesis also mandated, tracking for bleeding or infection. In case of peripheral 9 
ECMO, clinical and Doppler examination of the peripheral pulse should be part of the nurse 10 
surveillance, in order to promptly identify any lower limb ischemia. 11 
Ventilator Settings 12 
Ventilator settings should be adapted, in order to avoid ventilator-induced lung injury. 13 
Positive pressure ventilation may decrease left and increase right ventricular afterload. This 14 
can be either beneficial or detrimental depending on the global cardiac function. For instance, 15 
positive pressure ventilation may improve a pulmonary edema on the one hand, while 16 
worsening a right heart failure on the other hand. It is proposed to use a protective ventilation 17 
strategy with a Tidal Volume of 6 to 8 ml/kg of ideal body weight, with a maximum PEEP of 18 
10 cmH2O and/or a plateau pressure of 20-25 cmH2O, and to adjust the latter settings to the 19 
cardiorespiratory function [39]. The recent ELSO guidelines recommend the use of the 20 
smallest possible volume and pressure, in order to allow lung rest and recovery [31].  21 
Anticoagulation 22 
Anticoagulation therapy should also be used, except in presence of a specific bleeding risk. 23 
Potentially life threatening bleeding events are the most frequent complication during VA-24 
ECMO [40]. The extracorporeal circuit by itself induces an activation of the inflammatory 25 
13 
 
and the coagulation pathways. This, in turn, favor bleeding or clotting complications such as 1 
stroke or pulmonary embolism [41,42].  2 
In a study reporting 405 patients under VA-ECMO, the bleeding rate was 31% [42]. In a 3 
recent study, Aubron et al. [40] reviewed the complications of veno-venous and veno-arterial 4 
ECMO, and evaluated their impact on mortality. Bleeding was the most frequent adverse 5 
event (27 %), regardless of the type of ECMO. Moreover, the total number of transfused 6 
packed red blood cells was an independent predictor of death during VA-ECMO.  7 
On the other hand, avoiding anticoagulation could lead to thrombotic events including stroke. 8 
Indeed, clots in the extracorporeal circuit could lead to scatter emboli into the intracranial 9 
circulation. On addition, insertion of the arterial cannula into the aorta may damage an 10 
atherosclerotic intima, potentially resulting in emboli and multifocal cerebral infarctions. In 11 
Hemmila et al. study [42], 5.5% of the patients on VA-ECMO had ischemic neurological 12 
adverse events. When a CT scan was performed systematically, Lindegran et al. [41] reported 13 
a 45% rate of intracranial hemorrhage or infarction. Consistently, Mateen et al. [43] evaluated 14 
42 patients under VA-ECMO, and observed neurological events in 50% of them. However, in 15 
the latter study, VA-ECMO indication was refractory cardiac arrest in 16% of the patients, a 16 
condition highly prone to neurologic complication.  17 
Consequently, anticoagulation is necessary but has to be managed carefully during VA-18 
ECMO. Generalized use of heparine-coated circuit allows for low dose intravenous 19 
heparinization with a TCA ratio target around 1.5 [31]. This is especially possible if the pump 20 
rotation speed is high enough as the risk for clotting formation is maximal when the pump 21 
flow rate is below 1500 ml/min. 22 
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Infections and other Complications 1 
Aubron et al. [40] reported a high incidence of bloodstream infection (13% for va- and vv-2 
VA-ECMO). Hemmila et al. [42] reported a global infection rate of 38%. Consistently, a 3 
recent meta-analysis including 1,866 patients from 20 studies [44] confirmed the high 4 
infection rate under VA-ECMO (30 [20 - 44] %).   5 
Figure 3, using results of [44], summarizes the rates and the types of complication occurring 6 
during VA-ECMO for acute cardio-respiratory failure. 7 
Indications 8 
 9 
The main indication for VA-ECMO is cardiogenic shock resulting from acute myocardial 10 
infarction, fulminant myocarditis, acute decompensation of severe chronic heart failure, drug 11 
intoxication, hypothermia or intractable arrhythmia. VA-ECMO is also used in some specific 12 
situations such as post-cardiotomy cardiac failure or cardiac arrest requiring cardiopulmonary 13 
resuscitation. Furthermore, VA-ECMO is proposed for patients with pulmonary embolism, 14 
sepsis-associated cardiomyopathy and pulmonary hypertension.  15 
A recent meta-analysis pooled 23 studies (n=1,199) in which VA-ECMO was initiated to treat 16 
cardiogenic shock or refractory cardiac arrest. Long-term mortality was reported in 16 studies 17 
and overall one-year survival rate was 54.9% [45].  18 
Cardiac Arrest 19 
Over the past decade, there has been a growing interest for VA-ECMO in out-of-hospital 20 
refractory cardiac arrest. However, the benefit of VA-ECMO is apparently higher in patients 21 
with intra-hospital cardiac arrest [1,46–50]. This is confirmed in a recent observational 22 
propensity-matched study [51] including 320 VA-ECMO for cardiac arrest. Nevertheless, 23 
when reducing time to implantation, by implementing pre-hospital ExtraCorporeal Cardio-24 
15 
 
Pulmonary Resuscitation (eCPR), Lamhaut et al. found no difference in mortality between in- 1 
and out- of hospital cardiac arrest patients, resuscitated with VA-ECMO [52]. Cardiac arrest 2 
caused by hypothermia or poisoning have better outcomes than cardiac arrest due to other 3 
reasons [2,53–56]. The French council for cardio-pulmonary resuscitation as well as the 4 
French society of Anesthesiology and Intensive Care Medicine have limited the indications 5 
for VA-ECMO initiation in refractory cardiac arrest to “reasonable” low flow durations (< 6 
100 min), and to cardiac arrests resulting from poisoning or with deep hypothermia (< 32°C) 7 
[57]. North American guidelines still do not recommend VA-ECMO in this indication [58]. 8 
VA-ECMO has also been used for Post Cardiac Arrest syndrome (PCAS), i.e., patients 9 
suffering from a profound cardiogenic shock after return of spontaneous circulation. 10 
However, with or without VA-ECMO, mortality reaches 72 to 80% in this indication [59,60].  11 
 12 
Acute Cardiac failure 13 
Acute Coronary Syndrome (ACS)   14 
Even if European and American guidelines recommend VA-ECMO use in case of ACS 15 
leading to heart failure refractory to medical treatment, with IIa and IIb proof levels 16 
respectively [61,62], to our knowledge, no randomized study has ever reported any benefit of 17 
VA-ECMO as compared to medical treatment alone. These guidelines are only supported by 18 
results from observational series [3,63–65]. Indeed, a historical case-control study published 19 
in 2010 reported a benefit of VA-ECMO on 30-day survival (OR = 0.22 ; 95%CI [0.06-20 
0.80] ) in 71 patients with profound cardiogenic shock and acute coronary syndrome [65]. 21 
Mortality in the VA-ECMO group was 31.9 %. In a study on 98 patients, Sakamoto et al. [3] 22 
reported a much higher mortality rate (67 %). However, the latter study included patients on 23 
VA-ECMO for both cardiogenic shock and refractory cardiac arrest. In addition, VA-ECMO-24 
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related complications were frequent in this population, and this was associated with a worst 1 
prognosis (OR = 4.72 ; 95%CI [1.39–16.1]; p = 0.013). In an attempt to better identify the 2 
patients who benefit from VA-ECMO, Muller et al. identified 7 prognostic factors (age > 60, 3 
female sex, body mass index >25 kg/m
2
, Glasgow coma score < 6, creatinine > 150 μmol/L, 4 
lactate > 2, mmol/L, and prothrombin activity < 50%) in 138 patients under VA-ECMO for 5 
Acute Myocardial Infarction [66]. These factors entered into the ENCOURAGE score 6 
allowed to predict hospital mortality with an AUC of 0.84, 95%CI [0.77-0.91] 7 
Fulminant Myocarditis 8 
Fulminant myocarditis or intoxications with cardio-depressant agents are two of the best 9 
examples of a bridge to recovery situations. In this pathology, myocardial depression is 10 
usually transient and VA-ECMO is used to wait for heart function recovery. VA-ECMO has 11 
thus been used with good results and several studies reported survival rates as high as 60-70% 12 
[4,67].  VA-ECMO was shown to improve the outcome in this context [4,68].  13 
Septic Cardiomyopathy 14 
Myocardial depression is a well-recognized consequence of severe septic shock. Septic 15 
cardiomyopathy was reported in up to 60% of septic shocks [69]. Because this myocardial 16 
depression is potentially fully reversible, VA-ECMO was proposed with survival rate from 17 
observational series ranging from 21 to 85% [5,70,71]. However, the level of evidence is still 18 
too low to recommend VA-ECMO in this situation. 19 
Post cardiotomy cardiogenic shock 20 
Postcardiotomy cardiogenic shock occurs in approximately 1% of the patients after cardiac 21 
surgery. In such cases, VA-ECMO may be used as a bridge-to-recovery. However, survival 22 
rates in this indication are inconsistent, ranging from 24 to 39% [6,72].  23 
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Primary graft dysfunction (PGD) after transplantation 1 
Primary graft failure is the first cause of early mortality after heart, lung, and heart-lung 2 
transplantation. Data from the International Society for Heart Lung Transplantation (ISHLT) 3 
Transplant Registry show 66%, 24.7% and 27 % mortality rates attributable to primary graft 4 
dysfunction, during the first 30 days following heart, lung and heart-lung transplantation, 5 
respectively [73–75]. The ISHLT states that mechanical support is the only viable therapeutic 6 
option in this context. Indeed, VA-ECMO can improve survival rates (as high as 82%) of 7 
patients with graft dysfunction following lung [76] or heart [7,77,78] transplantation. 8 
Bridge to Destination Therapy 9 
Destination therapies may be considered for end-stage heart failures. They include either heart 10 
transplantation or long term Left Ventricular Assist Devices (LVAD). As for lung 11 
transplantation, acute decompensation of an end-stage heart failure is associated with a worse 12 
prognosis. In this context, VA-ECMO has been proposed to allow recovery from multiple 13 
organ failure. In 1999, Pagani et al. [79] reported the feasibility of VA-ECMO as a bridge to 14 
destination therapy. The overall survival for patients bridged using VA-ECMO either to 15 
LVAD or to transplantation was of 43%. After successful VA-ECMO initiation, survival rates 16 
reached 71% at one year. Further studies have reported survival rates ranging from 50% to 17 
73% [80] depending on whether the VA-ECMO was used as a bridge to LVAD (50%) or to 18 
transplantation (73%). “Bridge to bridge” VA-ECMO has also been reported: VA-ECMO 19 
used as a bridge to LVAD, the latter being used as a bridge to transplantation [81]. In this 20 
study, the use of VA-ECMO prior to LVAD did not affect mortality at 3 years (13% vs. 23%) 21 
or the duration of LVAD assistance (292 [153–448] vs. 311 [175–594] days). Analyses based 22 
on the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 23 
registry including approximately 15,000 patients showed that even if VA-ECMO improves 24 
the survival rate of patients during decompensation of end-stage diseases, it is a strong 25 
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predictor of poor outcome. Better results are observed when a LVAD is implanted in patients 1 
with a stable condition [82–84]. 2 
Indications to Initiate a VA-ECMO 3 
Because the risks associated with the technique are high, a thorough discussion about the best 4 
global therapeutic plan is mandatory, including: 1) the choice of the most appropriate 5 
cannulation site and type of assistance, 2) anticipation of the potential complications, and 3) 6 
of the weaning strategy. Thus, it is crucial to define whether the VA-ECMO is indicated as a 7 
bridge to recovery, to transplantation, or as a bridge to destination therapy [31,85].  8 
A “Bridge to recovery” is an assistance initiated to wait for the recovery of a reversible life 9 
threatening condition. Typical examples are acute cardiorespiratory failure resulting from 10 
acute myocarditis, intoxication with cardiac depressant agents, or coronary syndrome with 11 
cardiogenic shock. Prior to inserting the VA-ECMO, the physicians hope that the condition is 12 
reversible and that the failing organ will recover after a brief period of support. In the absence 13 
of potential reversibility and if none of the alternative support (transplantation or long-term 14 
assist device) is deemed feasible, VA-ECMO should not be implanted. 15 
VA-ECMO may be used as a “bridge to transplantation” when the failing organ no longer 16 
permits survival and needs to be supported. In this context, VA-ECMO may also allow for the 17 
recovery of organ dysfunction such as renal or liver failure or for an appropriate neurological 18 
evaluation after withdrawal of the sedation medications. 19 
In the “bridge to destination therapy”, VA-ECMO is used to support the heart while waiting 20 
for the possibility to implant a long-term mechanical assist device. This is indicated for end 21 
stage heart failure, when the patient is temporarily or definitely contraindicated to 22 
transplantation.  23 
19 
 
In the « Bridge to Bridge » strategy, VA-ECMO is implanted as a bridge to Left Ventricular 1 
Assist Device that is a more sustainable therapy allowing the patient to be discharged from 2 
the ICU, while waiting for a graft. 3 
 4 
  5 
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Weaning strategies 1 
 2 
After VA-ECMO insertion, daily cardiorespiratory evaluation should be performed to 3 
consider VA-ECMO weaning. Indeed, since this assistance carries complications, it is wise to 4 
consider withdrawing the VA-ECMO as soon as possible. The evaluation should answers the 5 
following questions : i- Has the cardiac function recovered ? ; ii- Has the respiratory function 6 
recovered ? ; iii- Could a favorable evolution be predicted ? ; iv- Could further 7 
cardiopulmonary aggression be predicted (open heart surgery for example) ? ; v- Will a 8 
removal of the assistance be well tolerated ? 9 
Weaning Eligibility 10 
Weaning from VA-ECMO should usually not be attempted within the first 48 hours, since 11 
renal and/or hepatic function should recover first. In addition, the etiology of cardio-12 
circulatory dysfunction must be compatible with myocardial recovery. Substantial myocardial 13 
recovery can be expected for acute myocarditis, acute myocardial infarction, post-cardiotomy 14 
cardiogenic shock or drug intoxication. On the contrary, in most cases, patients with end-stage 15 
cardiac disease cannot be taken off VA-ECMO unless for transplantation or insertion of a 16 
long-term assist device.  17 
To be eligible for VA-ECMO weaning, patients under VA-ECMO should be deemed 18 
hemodynamically stable: mean arterial pressure (MAP) of > 60 mmHg under low doses of 19 
vasopressors and a presence of a pulsatile arterial waveform maintained for at least 24 hours.  20 
Weaning Trial 21 
The weaning trial relies on a thorough clinical and echocardiographic examination. The goal 22 
is to assess whether the patient would tolerate to be separated from the VA-ECMO on both 23 
respiratory and hemodynamic standpoints. To do so, the VA-ECMO blood flow should be 24 
decreased progressively to a minimum of 1 L/min for at least 15 min and the sweep gas flow 25 
21 
 
rate reduced to 1 L/minute, with a FiO2 on the VA-ECMO at 21%. If the MAP drops 1 
significantly and is constantly < 60 mmHg during the trial, the VA-ECMO flow rate must be 2 
returned to 100% of the initial flow rate and the trial must be stopped. Echocardiography 3 
evaluation relies on the variables assessing LV systolic function (Left Ventricular Ejection 4 
Fraction - LVEF - and lateral mitral annulus peak systolic velocity), LV flow (aortic velocity-5 
time integral) and right ventricular diameters and function index (Tricuspid Annular Plane 6 
Systolic Excursion - TAPSE). The latter right ventricular function indicators are nevertheless 7 
nonconsensual. 8 
The oxygen fraction delivered by the extracorporeal circuit should be turned down to 21% 9 
and the one delivered by the ventilator should be less than 60%. The resulting PaO2/FiO2 10 
ratio should not be lower than 200.  11 
In summary, VA-ECMO removal can be considered if the patient does not have end-stage 12 
cardiac disease, tolerates well the weaning trial, and has a LVEF ≥ 20–25%, an aortic 13 
velocity-time integral ≥ 12 cm and a lateral mitral annulus peak systolic velocity ≥ 6 cm/s 14 
under minimal VA-ECMO support [86,87] .   15 
 16 
  17 
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Conclusion 1 
 2 
VA-ECMO is an extracorporeal technique that may support cardiorespiratory functions. 3 
Because this technique has substantially improved over time, VA-ECMO use is no longer 4 
restricted to the operating room and has spread to intensive care units. However, VA-ECMO-5 
related complications are potentially life threatening. Therefore, before starting a VA-ECMO 6 
program, it is mandatory to provide to the ICU staff a good understanding and practice of the 7 
technical aspects, including insertion of vascular accesses under cardiopulmonary 8 
resuscitation. In order to maximize the chances of success, it is of paramount importance to 9 
select carefully the patients who can benefit from VA-ECMO and to be able to have multi-10 
disciplinary discussions (involving intensivists, cardiac surgeons and cardiologists) about i) 11 
VA-ECMO indications, ii) chances of recovery, iii) the overall plan of care and iv) the 12 
appropriate VA-ECMO technique. Hence, the decision to initiate a VA-ECMO and the choice 13 
of the best method is best taken by a team of experienced physicians potentially associating 14 
intensivists, cardiologists and cardiac surgeons. 15 
16 
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Tables 1 
 2 
Table 1: Summary of studies per VA-ECMO indication 3 
Authors Year Type 
Cohort 
Size 
VA-
ECMO 
Sample 
size Mortality 
Favouring 
treatment 
       
Acute Coronary Syndrome 
 Fujimoto K [64] 2001 
Retrospective, 
Observational  
9 pts 56% Not Given 
 Chen JS [63] 2006 Prospective, Observational 
 
36 pts 33% Not Given 
 Sheu JJ [65] 2010 
Retrospective, 
Observational 
71 pts 46 pts 72% No 
        
Cardiac Arrest 
 Chen YS [88] 2003 
Retrospective, 
Observational 
 
57 pts 68% Not Given 
 Sung K [89] 2006 
Retrospective, 
Observational  
22 pts 54% Not Given 
 Megarbane B [2] 2007 Prospective, Observational 
 
17 pts 86% Not Given 
 Ruttmann E [90] 2007 
Retrospective, 
Observational 
59 pts 25 pts 72% Not Given 
 Chen YS [1] 2008 Propensity Matched 172 pts 46 pts 67% No 
 Chen YS [91] 2008 
Retrospective, 
Observational 
 
135 pts 66% Not Given 
 Lin JW [48] 2010 Propensity Matched 118 pts 27 pts 71% No 
 Le Guen M[92] 2011 Prospective, Observational 
 
59 pts 96% Not Given 
 Liu Y [93] 2011 
Retrospective, 
Observational 
 
11 pts 64% Not Given 
 Shin TG [94] 2011 Propensity Matched 406 pts 60 pts 68% Yes 
 Avalli L [46] 2012 
Retrospective, 
Observational  
42 pts 74% Not Given 
 Haneya A [95] 2012 
Retrospective, 
Observational 
 
85 pts 66% Not Given 
 Sakamoto S [3] 2012 
Retrospective, 
Observational 
 
64 pts 72% Not Given 
 Wu MY [96] 2012 
Retrospective, 
Observational  
40 pts 65% Not Given 
 Leick J [97] 2013 
Retrospective, 
Observational 
 
28 pts 61% Not Given 
 Maekawa K [98] 2013 Propensity Matched 162 pts 24 pts 69% Yes 
 Schopka S [50] 2013 
Retrospective, 
Observational 
 
103 pts 72% Not Given 
 Chou TH [47] 2014 
Retrospective, 
Observational 
66 pts  43 pts 65% No 
 Johnson NJ [99] 2014 Prospective, Observational 
 
26 pts 85% Not Given 
24 
 
 Kim SJ [100] 2014 Propensity Matched 499 pts 52 pts 85% No 
 Park SB [49] 2014 
Retrospective, 
Observational 
 
152 pts 68% Not Given 
 Sakamoto T [101] 2014 Prospective, Observational 454 pts 260 pts 88% Yes 
 Sawamoto K [53] 2014 
Retrospective, 
Observational 
 
26 pts 62% Not Given 
 Wang CH [102] 2014 Prospective, Observational 
 
230 pts 68% Not Given 
 Han SJ [103] 2015 
Retrospective, 
Observational 
  37 pts 81% Not Given 
 Choi DS [51] 2016 Propensity Matched 
36 227 
pts 
320 pts 82% No 
 
De Chambrun MP 
[59] 
2016 
Retrospective, 
Observational  
94 pts 73% Not Given 
 Bougouin W [60] 2017 
Retrospective, 
Observational  
52 pts 73% No 
 Lamhaut L [52] 2017 Prospective, Observational 156 pts 156 pts 87% Not Given 
        
Fulminant Myocarditis 
 Maejima Y [68] 2004 
Retrospective, 
Observational 
 
8 pts 25% Not Given 
 Rajagopal SK [67] 2010 
Retrospective, 
Observational  
255 pts 39% Not Given 
 Mirabel M [4] 2011 
Retrospective, 
Observational  
41 pts 34% Not Given 
        
Septic Myocarditis 
 Bréchot N [5] 2013 
Retrospective, 
Observational  
14 pts 39% Not Given 
 Huang CTH [104] 2013 
Retrospective, 
Observational  
52 pts 85% Not Given 
 Park TK [71] 2015 
Retrospective, 
Observational 
 32 pts 81% Not Given 
        
Post-Cardiotomy 
 Doll N [6] 2004 Prospective, Observational 
 
219 pts 76% Not Given 
 Rastan AL [72] 2009 Prospective, Observational 
 
517 pts 75% Not Given 
 Ma P [15] 2014 
Retrospective, 
Observational  
54 pts 61% Not Given 
        
Primary Graft Dysfunction 
 Mihaljevic T [77] 2010 Prospective, Observational 
 
53 pts 57% Not Given 
 Listijono DR [7] 2011 
Retrospective, 
Observational 
124 pts 17 pts 18% No 
 Stehlik J [73] 2011 
Retrospective, 
Observational 
10 271 
pts 
180 pts RR = 3,32 No  
 Hartwig MG [76] 2012 Prospective, Observational 
 
28 pts 18% Not Given 
 Lima EB [78] 2015 Prospective, Observational 
 
11 pts 67% Not Given 
        
Bridge to Destination Therapy 
 Pagani FD [79] 1999 Retrospective, 
 
14 pts 50% No 
25 
 
Observational 
 Chung [80] 2009 
Retrospective, 
Observational  
31 pts 39% Not Given 
 Marasco SF [81] 2015 
Retrospective, 
Observational 
58 pts 23 pts 13% Not Given 
        
pts : patients; RR : Relative Risk    1 
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Figures 1 
 2 
Figure 1: Schematic representation of cannulation ways for implantation of peripheral and 3 
central VA-ECMO. A - Centrally inserted veno-arterial ECMO ; B - Peripherally inserted 4 
veno-arterial ECMO 5 
 6 
Figure 2: Relationship Between Transmural Pressure (Ptm), Venous to Pump Pressure 7 
Gradient (Pp-v), and Venous Return Curve.  8 
Black arrows represent the strength and the direction of the forces inside the vein. Blue 9 
arrows represent the net forces applied to the wall of the vein 10 
The Venous Gradient (VG) is the difference between the Pressure in the venous system (Pv) 11 
and the pressure in the pump (Pp): VG = Pv - Pp. The Ptm is the difference between the 12 
Pressure inside (Pin) and outside (Pout) the vein: Ptm = Pin – Pout. The stronger the Pp-v, the 13 
higher the flow, until the critical point where the Pv exceeds the Ptm and leads the vein to 14 
collapse. 1) Decreasing the pump speed will decrease the VG and in turn will allow the blood 15 
to flow and/or 2) Giving fluid can increase the Pv and so the Ptm and can in turn allows the 16 
blood to flow 17 
 18 
Figure 3: Main complications reported during circulatory support with veno-arterial ECMO. 19 
Barplot realized using data obtained from meta-analysis given in [44]. Surgical Control of 20 
bleeding : Reintervention for bleeding at the insertion site. Haemorrhage : Bleeding 21 
complication others than insertion site (Gastro-Intestinal bleeding for example) 22 
 23 
 24 
  25 
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